Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Singulex, Inc.. (3/25/14). "Press Release: Singulex, in Partnership with Tecan, Commences Commercial Development of Ultrasensitive Sgx Clarity System for in vitro Diagnostics Market". Alameda, CA.

Organisations Organisation Singulex Inc.
  Organisation 2 Tecan Group Ltd. (SIX Swiss Exchange: TECN)
  Group Tecan (Group)
Products Product Freedom EVO® platform
  Product 2 Sgx Clarity™ System
Index term Index term Singulex–Tecan: automated liquid handling, 201403– collab developm of Sgx Clarity System using Freedom EVO platform
Person Person Baechler, Guido (Singulex 201305– CEO before SVP Operations joined 2008 before Roche Diagnostics)
     


- Fully-automated, bench-top system designed to be marketed by Singulex as an IVD and CE-marked device in the U.S. and global markets


Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMCTM) technology for clinical diagnostics and scientific discovery, today announced an agreement to co-develop the Sgx ClarityTM system with Tecan, a leading global provider of laboratory automation instruments. The partnership will incorporate Singulex's SMC technology and customized consumables onto Tecan's Freedom EVO® liquid handling platform. By integrating Singulex's proprietary ultrasensitive detection technology with Tecan's existing platform, Singulex expects to be able to commercialize the ultrasensitive immunoassay system for the in vitro diagnostics (IVD) market as early as 2016.

The Sgx Clarity System will be the most sensitive IVD immunoassay system for routine diagnostics. The fully-automated bench-top analyzer is targeted for clinical diagnostics laboratories and is being designed to be marketed by Singulex as an IVD and CE-marked device in the U.S. and global markets.

"We expect the Sgx Clarity System to be able to detect low-abundance biomarkers and pathogens with significantly greater sensitivity than any existing immunoassay IVD systems," said Guido Baechler, President and Chief Executive Officer of Singulex. "By choosing Tecan's innovative liquid handling platform, we are confident we will offer a fully-automated platform of the highest quality with a reduced time to market."


About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America.

The Freedom EVO® is a reliable, liquid handling tool and applications to automate a diverse range of applications including primary and secondary screening, cell growth and maintenance, nucleic acid sample preparation, hit picking, library management and sample weighing.


About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.

Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx ClarityTM System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.


Media:

Denise Powell
BrewLife
510.703.9491
dpowell@brewlife.com

Investors:

Chris Kim
Blueprint Life Science Group
415.375.3340
ckim@bplifescience.com

   
Record changed: 2017-04-02

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Singulex Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top